The arrival of generic semaglutide in Canada significantly improves the cost-effectiveness and affordability of recommended treatments for up to 2.1 million Canadians living with Type 2 diabetes who face a high risk of cardiovascular disease, according to a simulation study led by researchers at McGill University and t
The arrival of generic semaglutide in Canada significantly improves the cost-effectiveness and affordability of recommended treatments for up to 2.1 million Canadians living with Type 2 diabetes who face a...
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The arrival of generic semaglutide in Canada significantly improves the cost-effectiveness and affordability of recommended treatments for up to 2.1 million Canadians living with Type 2 diabetes who face a high risk of cardiovascular disease, according to a simulation study led by researchers at McGill University and t
Open the app view to save this story, compare related coverage, and continue from the same source.